<DOC>
	<DOCNO>NCT00961753</DOCNO>
	<brief_summary>The purpose study determine increase ibuprofen dose increase likelihood close patent ductus arteriosus premature baby .</brief_summary>
	<brief_title>Safety/Efficacy Study Optimizing Ibuprofen Dosing Achieve Higher PDA Closure Rates</brief_title>
	<detailed_description>Failure close PDA premature neonates timely fashion lead pulmonary over-circulation systemic under-circulation . The PDA often fail close use currently approve Ibuprofen dose regimen , surgical closure become necessary . Ibuprofen clearance premature neonates significantly correlate postnatal age , increase rapidly time . Hirt et al . publish optimized dose scheme preterm neonate base pharmacokinetic pharmacodynamic data . We aim use dose regimen clinical set determine increase rate pharmacologic PDA closure achieve .</detailed_description>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>All neonate ( 029 day old ) less equal 33 postmenstrual age time PDA diagnosis require nasal CPAP mechanical ventilation Echo confirm PDA transductal diameter 1.5 mm great demonstrate lefttoright shunt Signed informed consent Presence : ductaldependent congenital heart disease , pulmonary hypertension , Active bleeding ( include Grade 3 4 IVH ) Platelet count &lt; 100,000 Coagulopathy Suspected NEC Suspected perforation Creatinine &gt; 1.5 Hyperbilirubinemia require exchange transfusion Hypotension require pressor support Lifethreatening congenital malformation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Days</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>PDA</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>Preterm</keyword>
	<keyword>Neonate</keyword>
</DOC>